Tesamorelin

What it is

Tesamorelin (Egrifta) is a synthetic GHRH analog with structural modifications that enhance its half-life and biological activity compared to native GHRH. Specifically, tesamorelin is a 44-amino-acid peptide identical to native GHRH(1-44) with a trans-3-hexenoyl group attached to the N-terminus, which protects against DPP-4 cleavage and extends biological activity.

Tesamorelin was developed by Theratechnologies and received FDA approval in 2010 for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. This is its sole FDA-approved indication. Off-label use in metabolic medicine, particularly for visceral adiposity in non-HIV populations, has been an area of growing clinical interest.

Tesamorelin is FDA-approved and commercially manufactured but is also available through compounding pharmacies. Cost can be a barrier — commercial Egrifta is expensive and often not covered by insurance for off-label use.

Mechanism of action

Tesamorelin binds the pituitary GHRH receptor with affinity similar to native GHRH, stimulating endogenous, pulsatile GH release. The structural modifications produce a half-life of approximately 30 minutes — substantially longer than native GHRH (about 7 minutes) but still short enough to preserve pulsatile release patterns.

Key downstream effects:

• Visceral adipose reduction: elevated GH/IGF-1 promotes lipolysis preferentially in visceral fat depots, which are highly responsive to GH signaling. This is the basis for the FDA indication.
• Lipid profile improvement: reductions in triglycerides and improvements in HDL cholesterol have been documented.
• Body composition: visceral fat reduction with preservation of subcutaneous fat distribution and lean mass, producing favorable changes in waist circumference and metabolic risk markers.
• Possible modest effects on lean mass and exercise capacity, though smaller than with stronger GH-axis interventions.

Research findings

HIV-associated lipodystrophy (FDA approval indication): the pivotal Phase III trials demonstrated mean visceral adipose tissue (VAT) reductions of 15–18% over 26 weeks, with no significant change in subcutaneous fat. Continued therapy maintained the benefit; discontinuation led to gradual return toward baseline.

Non-HIV visceral adiposity: emerging studies in patients with general abdominal obesity, NAFLD/NASH, and metabolic syndrome have shown reductions in VAT and improvements in liver fat content. A 2018 study in NAFLD patients demonstrated reductions in liver fat content alongside VAT reduction.

Comparison to other GH secretagogues: tesamorelin produces more sustained IGF-1 elevation than sermorelin or CJC-1295 (no DAC), with correspondingly larger effects on visceral fat but somewhat higher rates of side effects related to elevated GH/IGF-1.

How we use it at The Tide

We prescribe tesamorelin selectively for:

• Patients with disproportionate visceral adiposity, often documented by waist-to-hip ratio, waist circumference, or imaging
• Patients with metabolic syndrome features who have not adequately responded to lifestyle interventions and other metabolic therapies
• Patients with documented liver fat accumulation (NAFLD) where visceral adiposity is a contributing factor
• Adjunct therapy in comprehensive metabolic protocols where adding GH-axis support is appropriate

Tesamorelin is more pharmacologically active than sermorelin or CJC-1295 (no DAC). We prescribe it when the clinical goal specifically calls for stronger GH-axis effects on visceral fat — not as a general “wellness” peptide.

Standard dosing: 1–2 mg subcutaneously daily, often used for 26-week courses in line with the trial dosing. Some protocols use shorter intermittent cycles.

Monitoring: baseline and 90-day IGF-1, fasting glucose and HbA1c (more important with tesamorelin than with weaker GH secretagogues given more pronounced effects on insulin resistance), comprehensive metabolic panel, lipid panel, weight, waist circumference, and patient-reported tolerability.

Side effects and contraindications

Side effects of tesamorelin can be more pronounced than weaker GH secretagogues, reflecting its more sustained GH/IGF-1 elevation:

• Joint discomfort and arthralgia — reflects fluid retention in synovial tissue from elevated GH
• Peripheral edema — particularly in lower extremities
• Paresthesias — tingling in hands and feet, sometimes carpal tunnel-like symptoms
• Glucose intolerance — GH antagonizes insulin action and can worsen insulin resistance
• Injection site reactions — rates higher than sermorelin in published trials
• Headache and fatigue in some patients

Contraindicated in:

• Active malignancy
• Pregnancy and breastfeeding
• Pituitary disease
• Severe diabetic retinopathy
• Uncontrolled diabetes (relative contraindication; may be considered with very careful glucose monitoring)

What we don’t yet know

Long-term cardiovascular outcomes of tesamorelin in non-HIV populations are not well characterized. Optimal cycle duration vs. continuous use for non-HIV indications remains debated. The role of tesamorelin in the modern era of GLP-1 dominance for metabolic disease is being redefined — for many patients, GLP-1 therapy now provides larger benefits with cleaner side effect profile, relegating tesamorelin to specific niche uses where targeted visceral fat reduction is the primary goal. Direct head-to-head comparisons against semaglutide or tirzepatide for visceral adiposity outcomes are not available. We present tesamorelin to patients honestly as a more potent but more side-effect-prone option among GH secretagogues, used selectively when the clinical scenario specifically calls for it.